ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Hepatitis B Core-Related Antigen is a Biomarker for off-Treatment Relapse After Long-Term Nucleos(t)ide Analog Therapy in Patients with Chronic Hepatitis B

Liao, Guichan; Ding, Xia; Xia, Muye; Wu, Yin; Chen, Hongjie; Fan, Rong; Zhang, Xiaoyong; Cai, Shaohang*; Peng, Jie*南方医科大学; 武汉大学
International Journal of General Medicine2021DOI: 10.2147/IJGM.S321253
6被引9阅读
引用收藏
分享

摘要

Objective: It remains unknown how to stratify the risk of clinical relapse of chronic hepatitis B (CHB) patients after stopping nucleos(t)ide analogs (NAs) antiviral therapy. @@@ Methods: The current post hoc analysis included 122 non-cirrhotic patients with chronic hepatitis B virus infection who were positive for hepatitis B envelope antigen (HBeAg) and discontinued long-term NA therapy after achieving HBeAg seroconversion for a median of 2.5 years. Post hoc analysis of end-of-treatment (EOT) hepatitis B core-related antigen (HBcrAg) levels was performed using a chemiluminescent enzyme immunoassay. @@@ Results: A total of 78/122 (63.9%) patients experienced sustained response after NAs cessation, and 44/122 (36.1%) patients experienced clinical relapse. In multivariate analysis, EOT HBcrAg (hazard ratio [HR] = 2.105 95% CI: 1.440-3.077, p < 0.001), hepatitis B surface antigen (HBsAg) >= 100 IU/mL (HR = 4.406, 95% CI 1.567-12.389, p = 0.005) and age (HR = 1.051, 95% CI: 1.010-1.093, p = 0.049) were independently associated with clinical relapse. A cut-off value of 4.0 log(10) U/mL of HBcrAg was defined by maximized Youden's index. An EOT HBcrAg level of >= 4.0 log(10) U/mL was associated with higher risks of clinical relapse (65.8% vs 23.2%, p<0.001) and HBeAg reversion (27.5% vs 1.6%, p < 0.001). In majority of patients (n = 91) who had a high EOT HBsAg level (>= 100 IU/mL), serum HBcrAg level could further discriminate patients at low risk of clinical relapse. Patients with an HBcrAg level >= 4.0 log 10 U/mL had significantly higher cumulative incidence rates of clinical relapse (78.1% vs 29.4%, p < 0.001) and HBeAg reversion (29.4% vs 0%, p < 0.001). @@@ Conclusion: Serum EOT HBcrAg level can be a predictor of off-treatment relapse in patients with CHB. An HBcrAg level of 4.0 log(10) U/mL may identify patients at high risk of clinical relapse after treatment cessation.

学科与关键词

关键词
chronic hepatitis Bdiscontinuationhepatitis B core-related antigenhepatitis B surface antigen
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
International Journal of General Medicine
发表日期
2021
卷期
第 14 卷
页码
4967-4976
DOI
10.2147/IJGM.S321253
期刊收录
NSL
期刊等级
3区
成果收录
SCIE
资助标注
National Science Foundation of China [81971949]; National Science and Technology Key Project on "Major Infectious Diseases such as HIV/AIDS, Viral Hepatitis Prevention and Treatment" [2017ZX09304016, 2017ZX10302201004008]; Clinical Research Startup Program of Southern Medical University by High-level University Construction Funding of Guangdong Provincial Department of Education [LC2016PY003]

作者

  • L

    Liao, Guichan (第一作者)

    southern med univ

  • D

    Ding, Xia

    southern med univ

查看全部 9 位作者收起作者
  • X

    Xia, Muye

    southern med univ

  • W

    Wu, Yin

    southern med univ · wuhan univ

  • C

    Chen, Hongjie

    southern med univ

  • F

    Fan, Rong

    southern med univ

  • Z

    Zhang, Xiaoyong

    southern med univ

  • C

    Cai, Shaohang (通讯)

    southern med univ

  • P

    Peng, Jie (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417